Cargando…

Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy

Ankylosing spondylitis (AS) is a type of spondyloarthropathies, the diagnosis of which is often delayed. The lack of early diagnosis tools often delays the institution of appropriate therapy. This study aimed to investigate the systemic metabolic shifts associated with AS and TNF inhibitors treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Jiayong, Xiao, Min, Huang, Yefei, Tu, Liudan, Chen, Zena, Cao, Shuangyan, Wei, Qiujing, Gu, Jieruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933516/
https://www.ncbi.nlm.nih.gov/pubmed/33679777
http://dx.doi.org/10.3389/fimmu.2021.630791
_version_ 1783660628491108352
author Ou, Jiayong
Xiao, Min
Huang, Yefei
Tu, Liudan
Chen, Zena
Cao, Shuangyan
Wei, Qiujing
Gu, Jieruo
author_facet Ou, Jiayong
Xiao, Min
Huang, Yefei
Tu, Liudan
Chen, Zena
Cao, Shuangyan
Wei, Qiujing
Gu, Jieruo
author_sort Ou, Jiayong
collection PubMed
description Ankylosing spondylitis (AS) is a type of spondyloarthropathies, the diagnosis of which is often delayed. The lack of early diagnosis tools often delays the institution of appropriate therapy. This study aimed to investigate the systemic metabolic shifts associated with AS and TNF inhibitors treatment. Additionally, we aimed to define reliable serum biomarkers for the diagnosis. We employed an untargeted technique, ultra-performance liquid chromatography-mass spectroscopy (LC-MS), to analyze the serum metabolome of 32 AS individuals before and after 24-week TNF inhibitors treatment, as well as 40 health controls (HCs). Multivariate and univariate statistical analyses were used to profile the differential metabolites associated with AS and TNF inhibitors. A diagnostic panel was established with the least absolute shrinkage and selection operator (LASSO). The pathway analysis was also conducted. A total of 55 significantly differential metabolites were detected. We generated a diagnostic panel comprising five metabolites (L-glutamate, arachidonic acid, L-phenylalanine, PC (18:1(9Z)/18:1(9Z)), 1-palmitoylglycerol), capable of distinguishing HCs from AS with a high AUC of 0.998, (95%CI: 0.992–1.000). TNF inhibitors treatment could restore the equilibrium of 21 metabolites. The most involved pathways in AS were amino acid biosynthesis, glycolysis, glutaminolysis, fatty acids biosynthesis and choline metabolism. This study characterized the serum metabolomics signatures of AS and TNF inhibitor therapy. We developed a five-metabolites-based panel serving as a diagnostic tool to separate patients from HCs. This serum metabolomics study yielded new knowledge about the AS pathogenesis and the systemic effects of TNF inhibitors.
format Online
Article
Text
id pubmed-7933516
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79335162021-03-06 Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy Ou, Jiayong Xiao, Min Huang, Yefei Tu, Liudan Chen, Zena Cao, Shuangyan Wei, Qiujing Gu, Jieruo Front Immunol Immunology Ankylosing spondylitis (AS) is a type of spondyloarthropathies, the diagnosis of which is often delayed. The lack of early diagnosis tools often delays the institution of appropriate therapy. This study aimed to investigate the systemic metabolic shifts associated with AS and TNF inhibitors treatment. Additionally, we aimed to define reliable serum biomarkers for the diagnosis. We employed an untargeted technique, ultra-performance liquid chromatography-mass spectroscopy (LC-MS), to analyze the serum metabolome of 32 AS individuals before and after 24-week TNF inhibitors treatment, as well as 40 health controls (HCs). Multivariate and univariate statistical analyses were used to profile the differential metabolites associated with AS and TNF inhibitors. A diagnostic panel was established with the least absolute shrinkage and selection operator (LASSO). The pathway analysis was also conducted. A total of 55 significantly differential metabolites were detected. We generated a diagnostic panel comprising five metabolites (L-glutamate, arachidonic acid, L-phenylalanine, PC (18:1(9Z)/18:1(9Z)), 1-palmitoylglycerol), capable of distinguishing HCs from AS with a high AUC of 0.998, (95%CI: 0.992–1.000). TNF inhibitors treatment could restore the equilibrium of 21 metabolites. The most involved pathways in AS were amino acid biosynthesis, glycolysis, glutaminolysis, fatty acids biosynthesis and choline metabolism. This study characterized the serum metabolomics signatures of AS and TNF inhibitor therapy. We developed a five-metabolites-based panel serving as a diagnostic tool to separate patients from HCs. This serum metabolomics study yielded new knowledge about the AS pathogenesis and the systemic effects of TNF inhibitors. Frontiers Media S.A. 2021-02-19 /pmc/articles/PMC7933516/ /pubmed/33679777 http://dx.doi.org/10.3389/fimmu.2021.630791 Text en Copyright © 2021 Ou, Xiao, Huang, Tu, Chen, Cao, Wei and Gu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ou, Jiayong
Xiao, Min
Huang, Yefei
Tu, Liudan
Chen, Zena
Cao, Shuangyan
Wei, Qiujing
Gu, Jieruo
Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
title Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
title_full Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
title_fullStr Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
title_full_unstemmed Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
title_short Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
title_sort serum metabolomics signatures associated with ankylosing spondylitis and tnf inhibitor therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933516/
https://www.ncbi.nlm.nih.gov/pubmed/33679777
http://dx.doi.org/10.3389/fimmu.2021.630791
work_keys_str_mv AT oujiayong serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy
AT xiaomin serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy
AT huangyefei serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy
AT tuliudan serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy
AT chenzena serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy
AT caoshuangyan serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy
AT weiqiujing serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy
AT gujieruo serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy